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Abstract
Background: Medication errors are an important source of potentially preventable morbidity and mortality. The PINCER
study, a cluster randomised controlled trial, is one of the world’s first experimental studies aiming to reduce the risk of such
medication related potential for harm in general practice. Bayesian analyses can improve the clinical interpretability of trial
findings.
Methods: Experts were asked to complete a questionnaire to elicit opinions of the likely effectiveness of the intervention for
the key outcomes of interest - three important primary care medication errors. These were averaged to generate collective
prior distributions, which were then combined with trial data to generate Bayesian posterior distributions. The trial data
were analysed in two ways: firstly replicating the trial reported cohort analysis acknowledging pairing of observations, but
excluding non-paired observations; and secondly as cross-sectional data, with no exclusions, but without acknowledgement
of the pairing. Frequentist and Bayesian analyses were compared.
Findings: Bayesian evaluations suggest that the intervention is able to reduce the likelihood of one of the medication errors
by about 50 (estimated to be between 20% and 70%). However, for the other two main outcomes considered, the evidence
that the intervention is able to reduce the likelihood of prescription errors is less conclusive.
Conclusions: Clinicians are interested in what trial results mean to them, as opposed to what trial results suggest for future
experiments. This analysis suggests that the PINCER intervention is strongly effective in reducing the likelihood of one of the
important errors; not necessarily effective in reducing the other errors. Depending on the clinical importance of the
respective errors, careful consideration should be given before implementation, and refinement targeted at the other errors
may be something to consider.
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Introduction
Frequentist and Bayesian Statistics: A Short Primer
The Bayesian perspective on statistical inference encapsulates
an inductive philosophical approach to statistics [1,2]. The
Bayesian paradigm provides several important benefits. One of
these benefits might be under-appreciated, given that many
interpret frequentist, sometimes also known as classical, confidence
intervals as providing intervals which contain the true effect with
some particular probability, say a 95% probability, when in fact
they provide information on likelihood of such an observation over
the course of many repetitions of the trial (so long as models are
well specified and sample sizes sufficiently large). However, the
Bayesian approach actually provides intervals such that the
posterior probability of the clinical effects lying within the interval
is indeed the afore-mentioned probability, say 95%, and so
therefore allows straight-forward interpretation of inferences on
the clinical important concepts. Whilst Bayesian inferences do also
allow direct statements about probabilities of effects, the Bayesian
paradigm is also upheld for moving the focus of interpretation
away from dichotomising whether the data suggest the in-
tervention works or not, i.e. by not claiming a ‘‘significant’’ or
‘‘null result’’, and more towards estimates of effect sizes, and so
switching focus to how clinically important the intervention is [3].
Bayesian methods also allow for the incorporation of evidence
additional to the conventional data [4,5]. This additional evidence
is called a prior distribution and summarises information from
external sources. This external evidence might take the form of
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subjective opinions or down-weighted less rigorous, or indirectly
related, results from previous studies [1,6]. Opinion-based prior
distributions might, for example, be based on sceptical opinions,
perhaps reflecting the belief that the intervention might be less
effective in routine practice (compared to the clinical trial setting);
or optimistic opinions reflecting the belief that the intervention
might be more beneficial in practice (compared to the clinical trial
setting) perhaps due to more flexible dosing titration for example
[7,8].
The use of Bayesian statistics within the applied medical
literature is growing, especially in the remits of early phase trials,
data monitoring, and adaptive randomisation techniques [9,10];
and towards the other end of the evidence hierarchy, Bayesian
methods are increasingly being used within evidence synthesis
[11,12]. However, use of Bayesian methods within the evaluation
of large-scale definitive trials is more limited [13–15]. In addition,
some Bayesian applications, whilst allowing for very complex
models, use off-the-shelf uninformative or vague prior distributions
(a prior which places equal weight across the entire range of values
and reflects no informative external information), and so don’t
fully incorporate the Bayesian paradigm, which includes knowl-
edge from all sources including expert opinions, [16,17]. Others,
where no other prior knowledge is available, use Bayesian methods
to allow the data to dominate, and again use uninformative or
vague prior distributions [18].
The Bayesian approach also naturally incorporates a sensitivity
analysis, although it is quite rare to do this, considering the
impact of various alternative prior distributions and sometimes
alternative models too [13]. Whilst analysis consistent with that
pre-specified in the trial protocol is essential to reduce selection
biases, sensitivity analyses acknowledge that many findings are
later rebutted [19].
Whilst frequentist methods can and do sometimes incorporate
sensitivity analyses, and frequentist analyses reporting only
confidence intervals also shift the focus away from statistical
significance, it is only the Bayesian approach that provides
a unified framework for this in addition to the incorporation of
expert opinions and intuitive interpretation of confidence intervals.
The PINCER Trial
Medication errors are common in general practice and are
associated with a substantial burden of iatrogenic harm. Our
previous systematic review of the literature found a dearth of
evidence from high quality randomised controlled trials on how
best to minimise this risk of patient harm [20]. Building on related
theoretical, descriptive and qualitative work, we developed and
piloted the PINCER intervention, which was then formally
investigated [21–23].
In summary, PINCER (registration number
ISRCTN21785299) was a large two arm UK-based cluster
randomised controlled trial, with ethical approval for the trial
from the Nottingham ethics committee (reference number: 05/
Q2404/26). This additional post-hoc analysis did not require
ethical approval as it constitutes a secondary re-analysis of existing
data and elicitation of the views of university academics. The trial
was undertaken in 72 practices that aimed to establish the
effectiveness and cost-effectiveness of a complex pharmacist-led
IT-enabled intervention compared with simple feedback to
practices in reducing the rate of clinically important errors in
medicines management in general practice. The three main
outcomes of interest related to reducing the proportions of patients
deemed at risk of the following potentially serious medication
errors:
N Patients with a peptic ulcer who are prescribed a non-steroidal
anti-inflammatory drug (NSAID);
N Patients with asthma who are prescribed a beta-blocker;
N Patients who are older than 75 years, prescribed an
angiotensin converting enzyme (ACE) inhibitor or loop
diuretic, and who have not had a renal or electrolyte
assessment in the past 15 months.
Further details of the PINCER trial and its main findings are
available from the trial protocol [24], and the published final
reports, with key findings discussed below [25,26].
Bayesian Analysis of the PINCER Trial
In this paper, we report the first Bayesian analysis of a service
delivery intervention [27]. These additional post-hoc Bayesian
analyses would, we anticipated, allow incorporation of subjective
opinions from experts in the field; intuitive interpretation of
confidence intervals; and also provide a framework from within
which it was possible to evaluate robustly sensitivity to model
specifications. We envisage that this would assist policymakers and
clinicians in making decisions on the basis of the current trial
findings (rather than giving estimates of how effective the trial
might prove if it was to be repeated). In the event, two different yet
legitimate statistical approaches yielded statistically significant and
null results for the same parameter of effectiveness; these results
were compared with the reported trial analysis which was pre-
specified in the trial protocol. This scenario enabled a contrast to
be drawn between the way results might be presented to decision
makers under frequentist and Bayesian analytical frameworks,
which naturally incorporates sensitivity analyses.
Methods
Experts
We purposefully selected a multi-disciplinary panel of individ-
uals with established interests/expertise in prescribing safety in
primary care contexts, whether from a clinical and academic, or
health policy context. The sampling frame was developed through
discussions amongst the research team on expert contacts, who
themselves had backgrounds in primary care, public health,
epidemiology and statistics, and our familiarity with the research
literature. The experts had no role in designing the study or vested
interest in its outcome. As one of the world’s first randomised
controlled trials aiming to improve prescribing safety in a primary
care context, the PINCER trial design is well known in specialist
circles. Furthermore, the detailed trial protocol was published and
available [24]. It was thus very likely that the experts had a good
appreciation of the trial’s aims and methods, which would inform
their estimates of likely effectiveness. We provided members of our
expert panel with a short summary of the trial, prior to their
completing the questionnaire, in an attempt to mitigate any
differences in prior knowledge about the study.
Elicitation Methods
Expert opinions were elicited using a structured interview form,
and followed best practice recommendations [4,5]. This form was
emailed electronically to all experts. Experts had the option of
completing the elicitation form themselves or through a structured
telephone interview with members of the study research team (KH
or PC). All opinions were elicited before any of the trial results
were presented at conferences, or published in peer-reviewed or
other publications. Please see Appendix S1 for a copy of the
elicitation form.
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The elicitation form included information on the three main
outcomes, including the estimated baseline event rate. Experts
were then asked for their opinion on the direction of any change
they expected in rates of errors, for both the intervention and
control groups. This very basic information was elicited to allow
validation of the consistency of the information elicited in the more
detailed information.
Experts were then informed that the trial was designed to detect
a relative reduction of 10% in the control arm and 50% in the
intervention arm. Provided with this information experts were
asked to provide their ‘‘best guess’’ of the relative reduction (20%
to 2100% for a decreasing rate, or +0% to +100% for an
increasing rate) in both arms; along with maximum and minimum
plausible ranges, which we described as representing their 95%
confidence interval. For example, the rate of Potential Error 1 was
estimated to be about 6% before the trial. An expert believing that
this might reduce to 3% in the control arm would need to express
this as a 250% relative reduction; and a similar opinion would
need to be provided for the change in the intervention arm.
Experts were told that their plausible ranges should represent an
effect size at the extreme 2?5% and 97?5% limits to roughly
represent their 95% confidence intervals.
Summarising Beliefs Elicited
The beliefs elicited from each of the experts were pooled to
obtain a collective prior distribution. Two different interpretations
of the elicited beliefs were considered.
The first interpretation of the beliefs was an optimistic
interpretation. Here it was assumed that the elicited maximum
(or minimum) plausible range in the intervention group was
concordant with the elicited maximum (or minimum) plausible
range in the control group. For example, suppose an expert
specified a reduction in the intervention arm of 50%, with 95%
interval 40% to 60%; and a reduction in the control arm of 20%,
with 95% interval 10% to 30%. This expert therefore believed that
the average relative risk for the intervention was 2.5 (i.e. 50/20).
Assuming concordance, between intervention and control arms, of
maximum and minimum values would mean that if in the
intervention arm the reduction was the at the lower of the specified
value (i.e. 40%), then in the control arm the reduction would also
be at the lower end of the specified value (i.e. 10%). Collectively
a reduction of 40% in the intervention arm and 10% in the
intervention arm equates to a relative risk of 4 (i.e. 40/10).
Similarly, assuming concordance of the upper beliefs specified in
both the intervention (60% reduction) and control arms (30%
reduction) would equate to a relative risk of 2 (i.e. 60/30). So
under this interpretation the belief elicited for the relative risk has
a 95% interval between 2 and 4.
The second interpretation was conservative. It might be the case
that the expert in the example above did not mean to specify the
maximum and minimum plausible ranges in a concordant way.
So, in the example above, a non-concordant interpretation of
a 95% range 40% to 60% in the intervention arm and 10% to
30% in the control arm, gives a maximum relative risk of 6 (i.e 60/
10) and a minimum of 1?3 (i.e. 40/30). This second interpretation
not assuming concordance between maximum (or minimum)
intervention and control limits, results in confidence ranges which
are wider and so less certain, and so is called a conservative
interpretation.
Both the conservative and optimistic beliefs for the relative risks
were then pooled over all experts, assuming normality on the log
scale, by taking averages of means and standard deviations,
obtained from the upper and lower confidence ranges, of
individual opinions. This then formed two (conservative and
optimistic) subjective prior distributions for the odds of reduction
in error rate comparing intervention to control.
Models for the PINCER Trial Data
The original analysis of the trial data was from a frequentist
perspective [26]. For the three primary outcomes, the original trial
analysis reported odds of reduction (intervention versus control) at
six months, estimated using random effects logistic models with
clustering at the practice level and adjustment for baseline
presence of the error and several practice level variables, with
95% confidence intervals. Practice level variables used within the
adjustments were: Index of Multiple Deprivation (IMD) score; list
size (three strata ,2500, 2500–6000, and .6000 patients); centre
(Manchester and Nottingham); and training status of the practice
(Yes/No) [24,25]. Only individuals with data at baseline and six
months were included in the original trial analysis. This trial-
reported analysis is consistent with recommendations of how to
analyse paired (i.e. baseline and follow-up) data, using what is
often described as an ANCOVA approach, which consists of
a regression type analysis including the baseline value as a covariate
[28]. This is henceforth referred to as the trial reported analysis in
all reporting of results and tabulations below.
In cluster randomised controlled trials, the study population
often forms a cohort population who are followed-up, and baseline
and follow-up measurements obtained on the same individuals.
Alternative designs, known as cross-sectional, use different
individuals at before and after time points [29]. The PINCER
study includes a mixture of the cohort and cross-sectional design:
some individuals are included at both baseline and follow-up,
whereas others are not.
Where there is a positive correlation between measurements,
then it has been established that an analysis that does not
acknowledge pairing is conservative; and that more precise
confidence intervals will be obtained from the analysis which
acknowledges the pairing [30]. However, a paired analysis
necessitates the exclusion of observations with either the baseline
or follow-up measurement missing. Excluding observations from
an analysis can have two consequences. The first of which is
a possible loss of precision by excluding observations, the size of
the dataset is reduced. The second consequence is the possibility of
biased estimates since those observations excluded from the
analysis might not be representative. There are techniques
available to mitigate the loss of information from observations
which have some missing covariate data (e.g. multiple imputation),
but even in a Bayesian framework these necessitate an assumption
of the missing data being missing at random.
So, an alternative way of analysing the PINCER study is to
consider the study as two cross-sectional studies, one before and
one after the intervention. This might or might not bring benefits
in terms of precision (depending on whether the benefit from the
pairing is greater than the benefit from the absolute increase in
numbers of observations). However, by not having to exclude any
observations, the cross-sectional analysis will not make any
assumptions about the nature of the reasons for missing follow-
up or baseline information, and so should provide the least biased
estimates.
We therefore compared two models, a cohort type approach
(i.e. consistent with the trial reported analysis) and cross-sectional
approach. In the cohort approach only individuals with both
before and follow-up measurements were included, the outcome
modelled was the presence of error at follow-up and covariates
included an indicator of intervention arm, and an indicator for
whether that individual was being prescribed in error at baseline.
In the cross-sectional analyses, the outcome was presence of error
Reducing Primary Care Errors: Bayesian Perspective
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and covariates included in the model were an indicator of time; an
indicator of intervention or control group; and an interaction
between time and intervention. The interaction term summarises
the effect of treatment after adjustment for baseline differences. All
models used logistic regression, adjusted for GP practice level
categorical variables (IMD score, list size and training status of
practice) and included a random effect for GP practice.
In summary, re-analysed the PINCER data from a frequentist
perspective but using a cross-sectional approach, this analysis is
referred to as the frequentist cross-sectional analysis. This was
compared to the trial reported analysis which we call the
frequentist cohort-analysis. The frequentist models, including only
the PINCER trial data, were fitted using StataSE version 11.2. We
then additionally combined the cohort and cross-sectional analyses
with the elicited prior distributions (methods outlined below).
Methods for Combining Prior Distributions with Trial
Data
For the Bayesian analysis we generated Bayesian posterior
distributions combining the elicited prior distributions with the
PINCER trial data, analysed from both a cohort and cross-
sectional perspective. All Bayesian analyses were performed using
the WinBUGS software with 100,000 iterations after allowing for
a 20,000 iteration burn-in and checking for convergence using
several common measures [31]. Summary estimates provided are
median and 95% Credible Intervals (CrI), which can be
interpreted as one would like to interpret a frequentist confidence
interval (i.e. an interval which contains the effect with 95%
probability). For parameters other than the treatment effect, we
used standard uninformative prior distributions [32]: uniform with
range 0 and 100 for the standard deviations; and normal
distribution centred at 0 and with variance 1,000 for other
parameters. Finally, we compared the analysis using the elicited
optimistic and conservative prior distributions with that of an
uninformative prior distribution for all parameters (i.e. by also
including a vague prior for the treatment effect parameter
normally distributed with mean 0 and variance 1,000). These
thus formed the Bayesian cohort and Bayesian cross-sectional
analyses.
Results
Thirty-four experts were approached via email. Of these, 15
agreed to participate; a further four responded stating they would
not like to participate (two because they had already seen the trial
results; one forwarded to a colleague; and one who was too busy);
and the remaining 15 failed to respond. Of the 15 responses
obtained, 11 responded directly by electronic completion of the
form and four responses were obtained by telephone interview.
One expert, whilst providing opinions for the first two outcomes,
did not feel able to provide an opinion on the third outcome.
Opinions provided by each of the experts are presented in Figure 1.
The conservative interpretations of the elicited opinions are much
less precise than those of the optimistic interpretation. Pooling
over experts the conservative and optimistic prior distributions are
shown in Table 1. Results are presented from the frequentist
analysis for the three outcomes and for both the cohort (Figure 2)
and cross-sectional analyses (Figure 3).
Reducing the Proportion of Patients with a Peptic Ulcer
who are Taking a NSAID
Experts generally agreed that the intervention should reduce
these rates to a greater degree in the intervention compared to the
control arm. The average estimated reduction (relative to baseline)
was 40% (95%CrI 15, 60) in the intervention, and 17% (95%CrI
4, 34) in the control arm. This translated into a collective averaged
belief (i.e. prior) of odds of reduction of error in intervention
practices of 0?74 (95%CrI 0?34, 1?63) under a conservative
interpretation; and a prior odds of reduction of 0?74 (95%CrI
0?59, 0?95) under an optimistic interpretation. Both these prior
distributions are centred on effect estimates which are slightly
smaller than that estimated by the trial reported analysis and with
less certainty (OR in trial reported analysis: 0?58 (95%CI 0?38,
0?89)).
The trial reported analysis for this variable included 3,434
paired observations; whereas the cross-sectional analysis included
7,664 individual observations (translating to an exclusion of 796
observations in the cohort analysis). Under the frequentist and
Bayesian approaches, both the cohort and cross-sectional analyses
were reasonably similar (Figures 2 and 3). This is suggestive of little
difference in both bias and precision between the two methods,
although the cohort analysis is somewhat more precise.
Reducing the Proportion of Patients with Asthma who
are Prescribed a Beta-blocker
Experts generally agreed again that the intervention should
reduce these rates to a greater degree in the intervention
compared to the control arm. The averaged best guess relative
(to baseline) reduction was 37% (95%CrI 14, 64) in the
intervention and 20% (95%CrI 6, 39) in the control arm. This
translated into a prior odds of reduction of 0?76 (95%CrI 0?24,
2.34) under a conservative interpretation; and a prior odds of
reduction of 0?76 (95%CrI 0?50, 1.15) under an optimistic
interpretation. Again, both these prior distributions were centred
on effect estimates which were slightly smaller than that estimated
by the trial’s reported analysis, with the optimistic prior mirroring
closely the trial reported analysis (OR 0?73; 95%CI 0?58, 0?91).
The trial reported analysis for this variable included 39,235
paired observations; whereas the cross-sectional analysis included
82,076 observations: meaning that the trial reported analysis
excluded 3,606 observations. Under the cross-sectional analysis,
both the frequentist and Bayesian analysis suggested that the
magnitude of the intervention may be less than that suggested by
the trial reported analysis, for example under the Bayesian analysis
with vague prior OR 0?88 (95%CI 0?75, 1?05). These translate
into estimates of reduction in odds of error of 27% and 12%. This
difference in findings between these two approaches suggests that
whilst power may be increased from the pairing (hence tighter
confidence and credible intervals under the cohort analysis)
patients without both before and after measurements are less
likely to have experienced a benefit from the treatment (Figures 2
and 3).
Reducing the Proportion of Patients Who are Older than
75 Years Taking an ACE Inhibitor or Loop Diuretic, Who
have not had A Renal or Electrolyte Assessment in the
Past 15 Months
Experts generally agreed once again that the intervention
should reduce these rates to a greater degree in the intervention
compared to the control arm. The average best guess relative (to
baseline) reduction was 43% (95%CrI 20, 61) in the intervention,
and 20% (95%CrI 7, 35) in the control arm. This translated into
a prior odds of reduction of 0?66 (95%CrI 0?31, 1?39) under the
conservative interpretation; and a prior odds of reduction of 0?66
(95%CrI 0?51, 0?85) under an optimistic interpretation. These
prior distributions were broadly similar to that estimated by the
trial’s reported analysis (0?51; 95%CI 0?34, 0?78).
Reducing Primary Care Errors: Bayesian Perspective
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The trial reported analysis for this variable included 8,185
paired observations; whereas the cross-sectional analysis included
19,251 observations: meaning that the trial reported analysis
excluded 2,881 observations. Under the cross-sectional analysis,
both the frequentist and Bayesian analysis, suggested the
magnitude of the intervention was very similar to that suggested
by the trial reported analysis, but that the precision was increased
under the cross-sectional analysis (Figures 2 and 3).
Discussion
Our Bayesian re-analysis of the PINCER trial, eliciting opinions
from experts in the field and incorporating these into a Bayesian
sensitivity analysis, additionally considering the influence of
modelling the data as cross-sectional or cohort, demonstrate that
the data consistently suggest that the intervention reduces the
likelihood of patients (.75years) on long term ACE inhibitor
medication, not having relevant renal checks, by on average
somewhere in the region of a 50% relative reduction, and that this
reduction would almost certainly be between 20% and 70%.
However, for the other two main outcomes, prescription of
NSAIDs in patients with a peptic ulcer and patients with asthma
who are prescribed a beta-blocker the evidence for effectiveness is
less certain and effect sizes probably smaller.
Policymakers and clinicians need to make decisions on the basis
of current trial findings. Reliance on P-values dichotomises results
and may mean that conclusions toggle from ‘non-significant’ to
‘significant’ depending on the analysis method. Confidence
intervals are beneficial in this regard, but frequentist confidence
intervals are prone to miss-interpretation and so Bayesian analyses
can be useful here. It might be argued that frequentist confidence
intervals are often good approximations to Bayesian credible
intervals, but with today’s computational power it is not necessary
to make such approximations. Furthermore, a Bayesian approach,
by considering the influence of choice of prior distribution on
inferences, naturally allows the incorporation of sensitivity
analyses. Sensitivity analyses are readily incorporated into
a frequentist analysis, but where sensitivity to analysis choice is
shown, then the impact of the sensitivity analysis can be at odds
with the desire to follow analysis methods pre-specified as primary
in the trial protocol.
Perhaps surprisingly, given the Bayesian approach might be
thought of as increasing the effective sample size, it has previously
been shown that Bayesian analyses often results in estimates which
are less certain when compared to their frequentist counterparts
[12]. This can be because the Bayesian model correctly acknowl-
edges that all model parameters are estimated with uncertainty,
Figure 1. Elicited expert opinions on three outcomes, under conservative and optimistic interpretations.
doi:10.1371/journal.pone.0038306.g001
Table 1. Elicited priors for log odds ratios and corresponding
95% Credible Intervals for the odds ratios.
Outcome
Optimistic
Prior
Conservative
Prior
Potential
Error 1
Log OR (mean, var) N(20.30,0.35) N(20.30,0.63)
OR [LCrI, UCrI] 0.74 [0.59,0.95] 0.74 [0.34,1.63]
Potential
Error 2
Log OR (mean, var) N(20.28,0.46) N(20.28,0.76)
OR [LCrI, UCrI] 0.76 [0.50,1.15] 0.76 [0.24, 2.34]
Potential
Error 3
Log OR (mean, var) N(20.42,0.36) N(20.42,0.62)
OR [LCrI, UCrI] 0.66 [0.51,0.85] 0.66 [0.31,1.39]
doi:10.1371/journal.pone.0038306.t001
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Figure 2. Cohort analysis of odds of error in control to intervention arm in the PINCER trial. The conservative and optimistic priors are
elicited expert priors. CI refers to frequentist confidence interval or credible interval for Bayesian analyses.
doi:10.1371/journal.pone.0038306.g002
Figure 3. Cross-sectional analysis of odds of error in control to intervention arm in the PINCER trial. The conservative and optimistic
priors are elicited expert priors. CI refers to frequentist confidence interval or credible interval for Bayesian analyses.
doi:10.1371/journal.pone.0038306.g003
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whereas in a frequentist approach some parameters, such as
variance parameters in random effects models, are assumed to be
estimated without uncertainty [12,13]. Methods which do not
acknowledge all parameter uncertainty will inappropriately
attenuate the estimated uncertainty.
The collective expert prior distributions, for all of the three
outcomes, were generally wider and less optimistic compared to
the frequentist estimates from the trial data. The experts were
therefore cautious in their certainty, but were optimistic for the
intervention. The three collective priors distributions, for each
of the three outcomes, were very similar suggesting that the
experts could discriminate little between the potential for
effectiveness of the intervention on each of the outcomes.
Because of the very large study sample sizes, their prior
opinions did not influence the posterior to a great extent. When
results toggle from ‘non-significant’ to ‘significant’ according to
the analysis undertaken, the Bayesian approach provides a guide
for decision makers by steering away from the frequentist P-
value, focuses on the range of uncertainty, and does not
dichotomise the results into yes, the intervention is effective, or
no, the intervention is not effective.
In addition to considering influence of expert opinions, we also
considered sensitivity to model choice. It is widely recognised that
the most efficient way to analyse paired before and after data are
by using ANCOVA methods [28]. This is consistent with viewing
a longitudinal study, like PINCER, as a cohort study, and indeed
this analysis was pre-specified in the trial protocol. Whilst this
recommendation is not disputed, in practical applications it is
important to consider the implications of excluding non-paired
observations on both precision and bias. An alternative approach
to analysis is thus to consider the study as a series of cross-sectional
studies, which, whilst not acknowledging the pairing of observa-
tions, does not require observations without both before and after
measurements to be excluded.
Strengths and Limitations of this Work
To our knowledge this is the first trial of a service level
intervention that has undertaken both frequentist analyses and
also reported on parallel Bayesian analysis, with subjective (as
opposed to uninformative) prior distributions. We are also we
believe the first to report the analysis of a cluster trial as
a mixture of the cohort and cross-sectional design. We took care
to ensure that members of our expert panel were not aware of
the trial results prior to eliciting their expert estimates, although
with hindsight this might not have been necessary [1].
Furthermore, to mitigate any differences in knowledge about
the study with provide all experts with basic information on the
values PINCER was powered to detect. This may have
inadvertently acted as an anchor, but elicited values did not
give cause for concern. The similarity between the opinions of
the experts and the trial data gives added confidence in the
external validity of the findings from this Bayesian analysis.
This work is however not without its potential limitations.
Opinions were elicited on the relative effects of the intervention
compared to the baseline for the control and intervention arms
independently, as recommended by O’Hagan and Stevens [2].
An alternative method would be to elicit opinions for the
relative effects of the control to intervention arms. However,
because the outcome of interest was the odds ratio this would
have meant eliciting a prior on an odds ratio scale, which may
have been confusing to the experts. Another potential limitation
is that we did not clearly specify the follow-up time for primary
outcomes (six months) when eliciting opinions, but as noted
above, given experts overall likely familiarity with the trial
design, this is unlikely to have had a major impact on the
findings from this work.
Implications for Policy, Practice and Future Research
The trial reported analysis should be dictated by the protocol
and so with this in mind the PINCER trial should be analysed as
a cohort study as originally intended. The trade-off in precision
between the two methods considered (cross-sectional versus
cohort) depends on the loss to follow-up. Estimates of these rates
of losses to follow-up could conceivably be estimated prior to the
start of a study and so required sample sizes (adjusted for loss to
follow-up) could be compared between both the cohort approach
and the cross-sectional approach. However, precision is not the
only important consideration and implications for bias are
important too. At the very extreme, analysis by cohort, excluding
all cases without before and after measurements, could indivertibly
exclude all patients who subsequently died of a medication error,
which is clearly not a fair comparison.
Although this additional analysis has, at face value, generated
results that are similar to the findings of those derived from the
trial reported analysis, it has also succeeded in presenting the
results as degrees of belief, the axiomatic method for formal
decision models, including health economic models. In this
particular study it illustrates a putative advantage from Bayesian
methods when different approaches to data analysis, neither of
which can be said to be wrong, proved a scenario in which results
are either significant or null according to method used. Finally, the
Bayesian approach of eliciting expert opinion prior to the
commencement of the study allows proper appreciation of
equipoise and might help determine whether a trial is ethical
[1]. Bayesian analyses of data should therefore be encouraged and
pursued more commonly.
This complex and post-hoc analyses of the PINCER trial
confirm that the intervention is likely to be effective in reducing
the potential for medication harm in general practice, but that
the only outcome for which the data suggest an unequivocal
reduction in risk is failure to carry out renal checks in those
(.75 years) on long term ACE inhibitor medication. For the
other two outcomes, prescription of beta-blockers in patients
with asthma, and NSAIDs in patients with peptic ulcers,
although the evidence points towards a reduction in risk, this
evidence is less certain.
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